HOME >> BIOLOGY >> NEWS
A New Look At Margerine And Health

Margarines are a healthy choice according to a CSIRO study.

The study, published recently in the American Journal of Clinical Nutrition, indicated that the benefits of polyunsaturated margarines are enhanced when they are also low in trans fatty acids, substances which raise total blood cholesterol.

Clinical trials conducted at CSIRO Human Nutrition in Adelaide, compared the effects of four types of margarine on blood cholesterol. The margarines were polyunsaturated or monounsaturated, with or without trans fatty acids. Thirty eight men and women with mildly elevated cholesterol took part in the feeding trial, lasting 11 weeks.

The results of the study showed that, compared to saturated fat spreads, any of the four margarines reduced the level of LDL (bad) cholesterol in the blood by 11 - 15 per cent. This corresponds to a fall in the risk of heart disease of approximately 20 - 30 per cent. HDL (good) cholesterol was unchanged. In an unexpected finding, the margarine high in polyunsaturates and low in trans fatty acids produced a greater fall in blood LDL-cholesterol than the other margarines.

"The margarine high in polyunsaturates and low in trans fatty acid lowered LDL-cholesterol a further 6 per cent compared to other margarines, a statistically significant difference", said CSIRO researcher Manny Noakes.

"Based on our data, the fall in heart disease risk could be reckoned to be 13 per cent greater with the polyunsaturated margarine without trans fatty acids than a similar spread with trans fatty acids."

Trans fatty acids are a minor class of fats found in small quantities in certain animal products. They used to be present in moderate quantities in margarines. However, there has been an international trend to reduce levels of trans fatty acids in margarines.

Approximately half the margarines on the Australian market do not contain trans fatty acids.

More information:
Manny Noakes, CSIRO, 08-83038827 or
Jenny Rhodes,
'"/>

Contact: Rosie Schmedding
rosie.schmedding@nap.csiro.au
61-2-6276-6520
CSIRO Australia
27-Nov-1998


Page: 1 2

Related biology news :

1. Health of worlds sea lions the focus of Wakefield Symposium
2. OneWorld Health compiles comprehensive state of infectious diarrhea treatments, potential solutions
3. Institute for OneWorld Health nominated for the 2004 World Technology Awards
4. Healthy fats and oils essential to satisfy calorie-conscious consumers
5. Institute for OneWorld Health receives Gates Foundation grant
6. Donaghue Womens Health Investigator Program awards grants to three at Yale
7. OneWorld Health CEO outlines mutually beneficial collaborations between industry, nonprofits at BIO
8. Addressing the Healthcare Needs of Our Aging Population with Technology
9. Institute for OneWorld Health CEO to speak at BIO on leveraging opportunities for global health
10. OneWorld Health completes enrollment, treatment in Phase III India trial
11. Institute for OneWorld Health CEO advocates focus first on developing world markets

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Look Margerine And Health

(Date:7/13/2015)... OXFORD, Conn. , Jul. 13, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... it has filed provisional patent 62/188684 for ... NXT-ID achieves another new convenient and secure method ... expands new, innovative payment methods, introduced with its ...
(Date:7/9/2015)... July 9, 2015  Unchained Labs just can,t ... acquisition of Avid Nano. Avid Nano designs, develops ... systems.    Also today, Unchained Labs ... easiest to use protein sizing system. The pUNk ... protein,s hydrodynamic size, size distribution, aggregation population and ...
(Date:7/8/2015)... LAKES , N.J. and NEW YORK ... Company) and Guidepoint today announced BD ... start-up healthcare companies with free access to Guidepoint,s expert ... several start-ups that are developing cutting-edge technologies to improve ... a dedicated Guidepoint research manager, each start-up entrepreneur will ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... advanced fluid applications and designed for continuous operation up to 1500 bar. The ... ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ NS2006L homogenizer is ...
(Date:7/29/2015)... 29, 2015 US-Australian drug discovery company, Novogen ... it is committed to progressing its ground-breaking technology platforms ... and to ensure the Company delivers the best value ... Iain Ross , said the Company currently had an ... programs, discovery programs and academic partnerships and initiatives, and ...
(Date:7/29/2015)... FRANCISCO , July 29, 2015  AsureQuality ... mobile molecular testing for applications in food and ... hand-held, battery powered real-time PCR device, the Freedom4. ... farm right through to the supermarket shelf for ... This includes involvement in animal disease control and ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
Cached News: